Series B opportunity E2 recently closed a $42M Series B financing in February 2025, indicating strengthened capital backing and potential for rapid product development and expansion of the Hēlo thrombectomy platform. This creates an opening to engage on capex-friendly procurement needs, clinical collaboration, and enterprise-scale manufacturing partnerships.

VTE focus The company targets venous thromboembolism with a next generation clot removal platform, offering a specialized niche for vascular access, interventional radiology, and cardiology product lines. Sales opportunities exist with hospitals and health systems expanding VTE treatment programs and investing in new thrombectomy technologies.

Clinical milestones Positive ENGULF study results and ongoing trials imply an evolving regulatory and adoption curve. Potential sales angles include early access programs, training, and integration with existing endovascular suites, as well as post-market data collection agreements.

Leadership momentum New CEO appointment in 2024 signals strategic market expansion and potential for scaled commercialization. Align outreach with leadership messaging on growth plans and partner ecosystems, emphasizing collaboration with large hospital networks and academic centers.

Strategic fit Work with mid to large health systems and contract manufacturers who can support scalable production, distribution, and training for a niche thrombectomy platform. Opportunities may include outsourcing, co-development, and clinical education programs to accelerate adoption.